XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

Core Insights - XOMA Royalty Corporation has acquired future royalty and milestone interests in mezagitamab from BioInvent for a total of USD $30 million, with an initial payment of USD $20 million at closing [1][2] - The acquisition enhances XOMA Royalty's late-stage royalty portfolio and provides BioInvent with non-dilutive capital to advance its clinical pipeline [2] - XOMA Royalty will be entitled to additional milestones of up to USD $16.25 million and mid-single digit royalties on future commercial sales of mezagitamab [3] Company Overview - XOMA Royalty Corporation is a biotechnology royalty aggregator that helps biotech companies by acquiring potential future economics associated with therapeutic candidates [5] - BioInvent International AB focuses on discovering and developing novel immune-modulatory antibodies for cancer therapy, currently having five drug candidates in clinical trials [6] Transaction Details - The economic interest in mezagitamab originated from a 2003 cross-licensing agreement between XOMA Royalty and BioInvent [2] - An additional payment of USD $10 million will be made upon mezagitamab achieving a specific regulatory milestone related to FDA marketing approval for IgA nephropathy [2] Clinical Development - Takeda, the developer of mezagitamab, has initiated a Phase 3 clinical trial for the treatment of immune thrombocytopenia (ITP) [4] - Mezagitamab is a fully human IgG1 monoclonal antibody targeting CD38, which has the potential to be a best-in-class anti-CD38 mAb [4]